Projecting the Long-Term Economic Impact of Once-Monthly Paliperidone Palmitate Versus Oral Atypical Antipsychotics in Medicaid Patients with Schizophrenia

BACKGROUND: Recent evidence has demonstrated that, over 12 months, pharmacy costs associated with switching nonadherent recently relapsed patients from oral atypical antipsychotics (OAAs) to once-monthly paliperidone palmitate (PP1M) were offset by reduced relapse rates and schizophrenia-related hea...

Descripción completa

Detalles Bibliográficos
Autores principales: El Khoury, Antoine C., Pilon, Dominic, Morrison, Laura, Shak, Nina, Llaneza, Amanda, Kim, Edward, Lefebvre, Patrick
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10390979/
https://www.ncbi.nlm.nih.gov/pubmed/32011960
http://dx.doi.org/10.18553/jmcp.2020.26.2.176

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10390979/
https://www.ncbi.nlm.nih.gov/pubmed/32011960
http://dx.doi.org/10.18553/jmcp.2020.26.2.176

Ejemplares similares